Reviews in pain最新文献_第2页

A systematic meta-review of hypnosis as an empirically supported treatment for pain 催眠作为一种经验支持的治疗疼痛的系统元综述

Reviews in pain Pub Date : 2001-06-01 DOI: 10.1191/0968130201PR175RA

R. Hawkins

引用次数: 44

Complex regional pain syndrome type I 复杂区域性疼痛综合征I型

Reviews in pain Pub Date : 2001-04-01 DOI: 10.1191/0968130201PR173RA

M. Kemler

{"title":"Complex regional pain syndrome type I","authors":"M. Kemler","doi":"10.1191/0968130201PR173RA","DOIUrl":"https://doi.org/10.1191/0968130201PR173RA","url":null,"abstract":"Complex regional pain syndrome type I (CRPS) is a chronic pain disorder involving the sensory, motor, and autonomic nervous systems, often leading to severe debilitation. Most commonly, a preceding limb injury catalyzes CRPS, although insidious onset has been known to occur. An estimated 60,000 Americans are affected by CRPS, including individuals between 25 and 55 years of age. CRPS is three times more likely to occur in women, although it can affect anyone [1]. Table 1 contains the CRPS clinical diagnostic criteria suggested by the International Association for the Study of Pain (IASP). Because of the poor understanding of the etiology of CRPS, its medical management is nebulous. Along with pain management, optimal treatment outcomes appear to be achieved when emphasizing functional restoration-a realm largely encompassed by physical therapists (PT). However, a review of the literature found that the term physical therapy is often used vaguely with no corresponding definition or description of procedures employed during treatment [2]. This has left PTs with a lack of guidance in treating patients with CRPS. The purpose of this case report is to describe the physical therapy management of a 38-year-old patient with CRPS developed from a chronic anterior talofibular ligament (ATFL) injury by using Active Release Techniques® (ART®) in combination with joint mobilization, gait training, therapeutic exercise, and education to document the observed clinical and functional improvements.","PeriodicalId":90719,"journal":{"name":"Reviews in pain","volume":"107 1","pages":"35-45"},"PeriodicalIF":0.0,"publicationDate":"2001-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80772730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 39

Pain, neurogenic inflammation and symmetry in medical practice 疼痛，神经源性炎症和医学实践中的对称性

Reviews in pain Pub Date : 2001-04-01 DOI: 10.1191/0968130201PR172RA

N. Shenker, R. Haigh, E. Roberts, P. Mapp, N. Harris, D. Blake

引用次数: 6

Are COX-2 selective inhibitors effective analgesics? COX-2选择性抑制剂是否有效?

Reviews in pain Pub Date : 2001-04-01 DOI: 10.1191/0968130201PR171RA

K. Mccormack, R. Twycross

引用次数: 4

Stellate ganglion block 星状神经节阻滞

Reviews in pain Pub Date : 2001-04-01 DOI: 10.1191/0968130201PR170RA

I. Marples, R. Atkinson

引用次数: 16

The role of morphine-6-glucuronide (M6G) in pain control 吗啡-6-葡萄糖醛酸盐(M6G)在疼痛控制中的作用

Reviews in pain Pub Date : 2001-01-01 DOI: 10.1191/0968130201PR183RA

Maree T. Smith, S. South

{"title":"The role of morphine-6-glucuronide (M6G) in pain control","authors":"Maree T. Smith, S. South","doi":"10.1191/0968130201PR183RA","DOIUrl":"https://doi.org/10.1191/0968130201PR183RA","url":null,"abstract":"Morphine-6beta-D-glucuronide (M6G) is an analgesically active metabolite of morphine, accounting for approximate to10% of the morphine dose when administered by systemic routes to humans. Although M6G is more hydrophilic than morphine, it crosses the blood-brain barrier, albeit relatively slowly. For this reason, it is generally thought that, after chronic dosing, M6G contributes significantly to the analgesic effects of systemically administered morphine. Owing to its polar nature, M6G is cleared from the systemic circulation primarily via renal elimination. As M6G accumulates in patients with renal impairment, there is an increased risk of M6G-induced respiratory depression in renal failure patients who are being dosed chronically with systemic morphine. Consistent with its analgesic and respiratory depressant properties, M6G binds to the p-opioid receptor in a naloxone-reversible manner. Although the affinity of M6G for the mu-opioid receptor is similar to or slightly less than that of morphine, preclinical studies in rodents show that M6G is one to two orders of magnitude more potent than morphine when administered by central routes. This major discrepancy between the markedly higher intrinsic antinociceptive potency of M6G relative to morphine, despite their similar p-opioid receptor binding affinities, is difficult to reconcile. It has been proposed that M6G mediates its pain-relieving effects through a novel 'M6G opioid receptor', while others have argued that M6G may have higher efficacy than morphine for transduction of intracellular events. When administered by parenteral routes to rodents, M6G's antinociceptive potency is no more than twofold higher than morphine. In humans, the analgesic efficacy and respiratory depressant potency of M6G relative to morphine have been assessed in a number of short-term studies involving the intrathecal or intravenous routes of administration. For example, in hip replacement patients, intrathecal M6G provided excellent postoperative analgesia but the occurrence of late respiratory depression in 10% of these patients raised serious concern about safety. In postoperative patients, intravenous M6G administered by means of patient-controlled analgesia (PCA), or bolus plus PCA, produced no analgesia in one study and limited analgesia in another. Similarly, there was a lack of significant analgesia in healthy volunteers who received intravenous M6G for the alleviation of experimental pain (carbon dioxide applied to the nasal mucosa). In contrast, satisfactory analgesia was produced by bolus doses of intravenous M6G administered to patients with cancer pain, and to healthy volunteers with experimentally-induced ischaemic, electrical or thermal (ice water) pain. Studies to date in healthy volunteers suggest that intravenous M6G may be a less potent respiratory depressant and have a lower propensity for producing nausea and vomiting than morphine. However, it is unclear whether equi-analgesic doses of M6G and m","PeriodicalId":90719,"journal":{"name":"Reviews in pain","volume":"2010 1","pages":"171-191"},"PeriodicalIF":0.0,"publicationDate":"2001-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73771178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Pre-emptive analgesia: recent findings 先发制人的镇痛:最近的发现

Reviews in pain Pub Date : 2000-07-01 DOI: 10.1191/096813000678809456

S. Aida, K. Shimoji

引用次数: 1

Capsaicin receptor and its homologue in nociception 辣椒素受体及其在痛觉中的同源物

Reviews in pain Pub Date : 2000-07-01 DOI: 10.1191/096813000678809447

M. Tominaga

引用次数: 4

Nociceptive and non-nociceptive rheumatological pain : recent understanding of pathophysiology and management in rheumatoid arthritis and fibromyalgia 痛觉性和非痛觉性风湿病痛:最近对类风湿关节炎和纤维肌痛的病理生理和治疗的认识

Reviews in pain Pub Date : 2000-07-01 DOI: 10.1191/096813000678809429

P. Dessein